Inefficient Induction of Neutralizing Antibodies against SARS-CoV-2 Variants in Patients with Inflammatory Bowel Disease on Anti-Tumor Necrosis Factor Therapy after Receiving a Third mRNA Vaccine Dose

Management of inflammatory bowel disease (IBD) often relies on biological and immunomodulatory agents for remission through immunosuppression, raising concerns regarding the SARS-CoV-2 vaccine’s effectiveness. The emergent variants have hindered the vaccine neutralization capacity, and whether the t...

Descripción completa

Detalles Bibliográficos
Autores principales: López-Marte, Paola, Soto-González, Alondra, Ramos-Tollinchi, Lizzie, Torres-Jorge, Stephan, Ferre, Mariana, Rodríguez-Martinó, Esteban, Torres, Esther A., Sariol, Carlos A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9414888/
https://www.ncbi.nlm.nih.gov/pubmed/36016189
http://dx.doi.org/10.3390/vaccines10081301

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9414888/
https://www.ncbi.nlm.nih.gov/pubmed/36016189
http://dx.doi.org/10.3390/vaccines10081301

Ejemplares similares